摘要
目的探讨CT引导下125I放射性粒子植入治疗骨转移瘤的临床效果。方法回顾性分析三二〇一医院2016年6月至2018年7月接受粒子植入治疗的43例骨转移瘤患者资料,共计52个病灶接受125I放射性粒子植入治疗。术后进行随访,根据疼痛缓解情况、生命质量改善情况及全身骨显像结果评估疗效。结果43例骨转移患者125I放射性粒子植入术后1、3、7、30、60、90、180 d疼痛缓解例数分别为19、32、39、36、36、34、31例,缓解率分别为44.19%、74.28%、90.70%、83.72%、79.07%、72.09%。术后7 d疼痛缓解率最高,且疼痛程度较治疗前下降,差异有统计学意义(Z=-5.216,P<0.05)。125I放射性粒子植入前后患者生命质量情况比较,差异有统计学意义(Z=-4.308,P<0.05)。术后3~6个月复查,45个骨转移病灶代谢减低、缩小,有效率为86.54%(45/52)。结论125I放射性粒子植入治疗骨转移瘤患者近期疗效较好,可有效缓解疼痛、提高局部控制率、改善生命质量。
Objective To explore the clinical efficacy of CT-guided 125I radioactive seed implantation in the treatment of bone metastases.Methods The data of 43 patients with bone metastases treated by seed implantation from June 2016 to July 2018 in the 3201 Hospital was retrospectively analyzed.The 52 lesions of 43 patients with bone metastases were treated with 125I radioactive seed implantation.The patients were followed up,and the efficacy was evaluated based on pain relief,quality of life improvement,and whole body bone imaging.Results The number of pain relief patients in 43 patients with bone metastases at 1,3,7,30,60,90,and 180 d after 125I radioactive seed implantation were 19,32,39,36,36,34,and 31 cases;the pain relief rates were 44.19%,74.28%,90.70%,83.72%,79.07%,and 72.09%,respectively.The pain relief rate was highest at 7 d after seed implantation,and the pain degree after seed implantation was significantly lower than that before seed implantation,the difference was statistically significant(Z=-5.216,P<0.05).The difference in quality of life between patients before and after 125I radioactive seed implantation was statistically significant(Z=-4.308,P<0.05).The re-examination in 3 to 6 months after treatment showed that the metabolism of 45 bone metastases lesions was reduced and shrunk,and the efficiency rate was 86.54%(45/52).Conclusion 125I radioactive seed implantation has good curative effect in the treatment of patients with bone metastases,which can effectively relieve pain,improve local control rate,and improve patients'quality of life.
作者
焦婉
付伟
司小敏
张消
王健庄
何文静
Jiao Wan;Fu Wei;Si Xiaomin;Zhang Xiao;Wang Jianzhuang;He Wenjing(Department of Oncology,Xianyang Central Hospital of Shaanxi Province,Xianyang 712000,China;Department of Intervention,3201 Hospital,Hanzhong 723000,China)
出处
《肿瘤研究与临床》
CAS
2020年第4期285-288,共4页
Cancer Research and Clinic